<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905069</url>
  </required_header>
  <id_info>
    <org_study_id>U0702</org_study_id>
    <nct_id>NCT04905069</nct_id>
  </id_info>
  <brief_title>Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy</brief_title>
  <acronym>SABRE</acronym>
  <official_title>Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the effectiveness of the SpaceOAR Vue System in reducing late gastrointestinal&#xD;
      (GI) toxicity in subjects undergoing Stereotactic Body Radiotherapy (SBRT) to treat prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">November 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Gastrointestinal (GI) Toxicity</measure>
    <time_frame>3 to 24 months post-SBRT initiation</time_frame>
    <description>Proportion of subjects experiencing late GI toxicity after SBRT treatment with or without placement of the SpaceOAR Vue System hydrogel. Late GI toxicity is defined as the occurrence of a Grade 2 or greater GI adverse event (NCI CTCAE v4) between 3- and 24-months post-SBRT initiation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EPIC-26 bowel score</measure>
    <time_frame>24 months post-SBRT initiation</time_frame>
    <description>Proportion of subjects experiencing a decrease in EPIC-26 bowel score greater than or equal to the minimal important difference (MID) in EPIC-26 bowel score from baseline to 24 months post-SBRT initiation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>No-Spacer Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will receive radiotherapy without the use of the SpaceOAR Vue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SpaceOAR Vue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpaceOAR Vue System</intervention_name>
    <description>The SpaceOAR Vue System is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of the SpaceOAR Vue System to reduce the radiation dose delivered to the anterior rectum.&#xD;
The SpaceOAR Vue System is composed of biodegradable material, maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.</description>
    <arm_group_label>SpaceOAR Vue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old.&#xD;
&#xD;
          -  Subjects must have pathologically confirmed (by routine hematoxylin and eosin (H&amp;E)&#xD;
             staining) invasive adenocarcinoma of the prostate and must have been planning to&#xD;
             undergo SBRT.&#xD;
&#xD;
          -  Subjects must have one or more of the following:&#xD;
&#xD;
          -  Clinical Stage T2b - T2c (AJCC 6th edition) tumor&#xD;
&#xD;
          -  Gleason Score 7 as determined from a biopsy taken within 6 months of the&#xD;
             baseline/screening visit&#xD;
&#xD;
          -  Demonstrated blood PSA levels 10-20 ng/ml as measured during the Subject&#xD;
             Enrollment/Baseline visit&#xD;
&#xD;
          -  Subject or authorized representative was informed of the nature of the study and&#xD;
             provided written informed consent, approved by the appropriate Institutional Review&#xD;
             Board (IRB)/Ethics Committee (EC) of the respective clinical site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prostate &gt;80 cc documented within 3 months preceding the Screening/Baseline visit&#xD;
&#xD;
          -  Clinical stage T3 or T4 (AJCC 6th edition) tumor&#xD;
&#xD;
          -  Blood PSA level &gt;20 ng/ml as measured during Subject Enrollment/Baseline visit&#xD;
&#xD;
          -  Gleason Score ≥ 8&#xD;
&#xD;
          -  Subjects who had MRI evidence of posterior extracapsular extension (ECE) of the&#xD;
             prostate cancer. Subjects who had metastatic disease, other ongoing cancers which were&#xD;
             treated during the study or subjects for whom pelvic lymph node radiotherapy was&#xD;
             planned.&#xD;
&#xD;
          -  Subjects with any prior invasive malignancy (except non-melanomatous skin cancer)&#xD;
             unless the subject had been disease free for a minimum of 3 years.&#xD;
&#xD;
          -  History of prostatectomy, transurethral prostate surgery (e.g. TUNA, TUMT, TURP) if&#xD;
             performed within 1 year prior to screening, other local prostate cancer therapy e.g.,&#xD;
             cryotherapy or brachytherapy) or previous pelvic irradiation at any time prior to&#xD;
             screening.&#xD;
&#xD;
          -  History of prior pelvic surgery requiring low anterior or abdominoperineal resections&#xD;
             or rectal surgery.&#xD;
&#xD;
          -  History of or active inflammatory bowel disease (IBD) such as Crohn's disease,&#xD;
             ulcerative colitis, or irritable bowel disease.&#xD;
&#xD;
          -  History of or current perirectal disease that may interfere with interpretation of&#xD;
             study outcomes including anal or perianal diseases such as fistula.&#xD;
&#xD;
          -  Bleeding hemorrhoids requiring medical intervention within the prior three months.&#xD;
&#xD;
          -  Active bleeding disorder or a clinically significant coagulopathy defined as a Partial&#xD;
             Thromboplastin Time (PTT) &gt;35s or International Normalized Ratio (INR) &gt; 1.4 or&#xD;
             platelet count less than 100,000 per mm³. Note: Patients on anticoagulants may be&#xD;
             included if the anticoagulant medication can be discontinued for index procedure.&#xD;
&#xD;
          -  Active inflammatory or infectious process involving the perineum, gastrointestinal&#xD;
             (GI) or urinary tract based on positive diagnosis or suspected diagnosis in the&#xD;
             presence of fever &gt;38⁰ C, WBC &gt; 12,000/uL.&#xD;
&#xD;
          -  Compromised immune system: WBC &lt; 4000 /uL or &gt; 12,000/uL or prior diagnoses for human&#xD;
             immunodeficiency virus (HIV) (with a detectable viral load within the last 6&#xD;
             months)/acquired immunodeficiency syndrome (AIDS) or autoimmune disease.&#xD;
&#xD;
          -  Contraindication for safe MRI, implants, or other conditions that would interfere with&#xD;
             imaging required for the study (e.g., Non-MRI compatible pacemaker or metal that&#xD;
             negatively impacts the MRI image at the discretion of the investigator).&#xD;
&#xD;
          -  If a subject was enrolled in another investigational drug or device trial that had not&#xD;
             completed the primary endpoint or that clinically interfered with this study.&#xD;
&#xD;
          -  Unable to comply with the study requirements or follow-up schedule.&#xD;
&#xD;
          -  Any condition the Investigator believed would interfere with the intent of the study&#xD;
             or would make participation not in the best interest of the patient.&#xD;
&#xD;
          -  Known iodine sensitivity or allergy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suneil Jain, MB, BCh, MRCP, FRCR, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University, Belfast</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blake Hedstrom</last_name>
    <phone>952-930-6000</phone>
    <email>blake.hedstrom@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kat Rainbow</last_name>
    <phone>952-930-6000</phone>
    <email>kat.rainbow@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GenesisCare USA</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susmita Jain, MS</last_name>
      <phone>248-589-5000</phone>
      <email>Susmita.Jain@usa.genesiscare.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Boike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>SBRT</keyword>
  <keyword>Spacer</keyword>
  <keyword>SpaceOAR</keyword>
  <keyword>SpaceOAR Vue</keyword>
  <keyword>Hypofractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

